Eli Lilly agreed to buy Ventyx Biosciences for $1.2 billion to add an oral NLRP3 inhibitor to its inflammation and metabolic portfolio. Ventyx’s lead candidate, VTX3232, showed biomarker and metabolic effects in earlier studies and is being tested across cardiometabolic and neurologic indications. Lilly positioned the deal to accelerate oral, small-molecule anti‑inflammatory options that could complement its obesity and metabolic franchise.